U.S. Markets open in 5 hrs 10 mins
  • S&P Futures

    4,196.00
    +1.75 (+0.04%)
     
  • Dow Futures

    34,451.00
    +9.00 (+0.03%)
     
  • Nasdaq Futures

    13,608.50
    +10.75 (+0.08%)
     
  • Russell 2000 Futures

    2,242.20
    +2.30 (+0.10%)
     
  • Crude Oil

    64.65
    -0.06 (-0.09%)
     
  • Gold

    1,820.80
    +5.10 (+0.28%)
     
  • Silver

    27.43
    -0.03 (-0.10%)
     
  • EUR/USD

    1.2085
    +0.0016 (+0.1329%)
     
  • 10-Yr Bond

    1.5610
    0.0000 (0.00%)
     
  • Vix

    18.47
    -0.68 (-3.55%)
     
  • GBP/USD

    1.3927
    +0.0034 (+0.2479%)
     
  • USD/JPY

    109.1500
    +0.0650 (+0.0596%)
     
  • BTC-USD

    55,636.39
    -1,306.70 (-2.29%)
     
  • CMC Crypto 200

    1,450.98
    -20.43 (-1.39%)
     
  • FTSE 100

    7,101.05
    +24.88 (+0.35%)
     
  • Nikkei 225

    29,357.82
    +26.45 (+0.09%)
     

9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

RALEIGH, NC / ACCESSWIRE / April 21, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that management will participate in the 7th Annual Truist Securities Life Sciences Summit and invites investors to participate in one-on-one meetings. Please see additional details below:

Truist Securities 7th Annual Life Sciences Summit

Date: May 4 - 5, 2021
Participation: Management will be available for 1-on-1 meetings virtually

Please contact your representative at Truist Securities to schedule a virtual one-on-one meeting with 9 Meters during the respective conference.

For more information about the Truist Securities 7th Annual Life Sciences Summit, please refer to the conference website.

About 9 Meters Biopharma
9 Meters Biopharma, Inc. ("the Company") is a rare and unmet needs-focused gastroenterology company. The Company is advancing NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for short bowel syndrome (SBS), a rare, orphan disease, as well as larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease.

For more information, please visit www.9meters.com or follow 9 Meters on Twitter and LinkedIn.

Forward-looking Statements
This press release includes forward-looking statements based upon the Company's current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) uncertainties associated with the clinical development and regulatory approval of product candidates; (ii) risks related to the inability of the Company to obtain sufficient additional capital to continue to advance these product candidates and its preclinical programs; (iii) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (iv) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (v) the impact of COVID-19 on our operations, clinical trials or future financings and (vi) risks associated with the possible failure to realize certain anticipated benefits of the Company's 2020 merger and its acquisition of Naia Rare Diseases, Inc. in 2020, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements because of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings that the Company has made and future filings the Company will make with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

CORPORATE CONTACT:
Edward J. Sitar
Chief Financial Officer
9 Meters Biopharma, Inc.
investor-relations@9meters.com
www.9meters.com

MEDIA CONTACT:
Amy Jobe, Ph.D.
LifeSci Communications, LLC
ajobe@lifescicomms.com
315-879-8192

INVESTOR CONTACT:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

SOURCE: 9 Meters Biopharma



View source version on accesswire.com:
https://www.accesswire.com/641239/9-Meters-Biopharma-Inc-to-Participate-in-the-Truist-Securities-7th-Annual-Life-Sciences-Summit